Bone is the second most common metastatic site in patients presenting with metastatic renal cell carcinoma. Bisphosphonates have been approved to reduce bone pain and the risk of skeletal-related events (SREs) in such patients; however, new research suggests bisphosphonates do not improve survival or prevent development of SREs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Woodward, E. et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48, 160–166 (2011).
Beuselinck, B. et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann. Oncol. 22, 794–800 (2011).
Lipton, A., Zheng, M. & Seaman, J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98, 962–969 (2003).
Keizman, D. et al. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur. J. Cancer 48, 1031–1037 (2012).
Keizman, D., Ish-Shalom, M., Maimon, N. & Gottfried, M. Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases? World J. Urol. 32, 39–45 (2014).
McKay, R. R. et al. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.02.040.
Wirth, M. et al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.02.014.
Saad, F. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol. 23, 1341–1347 (2012).
McArthur, H. L. et al. Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC). J. Clin. Oncol. (Meeting Abstracts) 26, 9588 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Roos, F. Bisphosphonates in the era of antiangiogenic targeted therapy. Nat Rev Urol 11, 315–316 (2014). https://doi.org/10.1038/nrurol.2014.120
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.120
